share_log

I-Mab (NASDAQ:IMAB) Stock Position Boosted by Nomura Holdings Inc.

Financial News Live ·  Mar 12, 2023 01:23

Nomura Holdings Inc. boosted its stake in I-Mab (NASDAQ:IMAB – Get Rating) by 0.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,613,214 shares of the company's stock after buying an additional 8,000 shares during the period. Nomura Holdings Inc. owned 3.14% of I-Mab worth $10,479,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMAB. Northwestern Mutual Wealth Management Co. acquired a new stake in I-Mab in the 2nd quarter valued at about $45,000. Acadian Asset Management LLC acquired a new stake in I-Mab in the 1st quarter valued at about $65,000. ExodusPoint Capital Management LP acquired a new stake in I-Mab in the 3rd quarter valued at about $42,000. OLD Mission Capital LLC acquired a new stake in I-Mab in the 3rd quarter valued at about $45,000. Finally, Virtus ETF Advisers LLC lifted its holdings in I-Mab by 265.0% in the 2nd quarter. Virtus ETF Advisers LLC now owns 11,446 shares of the company's stock valued at $129,000 after acquiring an additional 8,310 shares during the last quarter. Institutional investors own 37.02% of the company's stock.

Get I-Mab alerts:

I-Mab Price Performance

Shares of NASDAQ IMAB opened at $3.70 on Friday. I-Mab has a twelve month low of $3.19 and a twelve month high of $21.44. The firm has a 50-day moving average of $5.29 and a two-hundred day moving average of $4.63.

I-Mab Profile

(Get Rating)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.

Featured Articles

  • Get a free copy of the StockNews.com research report on I-Mab (IMAB)
  • MarketBeat Week in Review – 3/6 – 3/10
  • 2 Offshore Drilling Stocks Set to Extract Big Profits
  • Three Staples Stocks With Double-Digit Upside Ahead
  • Can Investors Trust Consumers to Lift American Outdoor Brands?
  • How to Buy High Yielding Dividend Stocks

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment